Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer

Abstract

The nivolumab with bevacizumab combination appeared to show activity in patients with relapsed ovarian cancer, with greater activity in the platinum-sensitive setting. Alternative combinational strategies may be necessary in the platinum-resistant setting.